Industrials, Financials, Technology May 20, 2022 05:04 PM (GMT+8) · EqualOcean
Fosun Pharmaceutical announced that the holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. launched phase II clinical research on fs-1502 (i.e. recombinant HER2 humanized monoclonal antibody monomethylorestatin f coupling agent for injection) for the treatment of non-small cell lung cancer (NSCLC) in China (excluding Hong Kong, Macao and Taiwan).